Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,266 as of Friday, Dec. 20, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,274 issues advancing vs. 691 declining with 120 unchanged. The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 4.7%, Regeneron Pharmaceuticals ( REGN), up 0.9%, Celgene Corporation ( CELG), up 1.6%, Amgen ( AMGN), up 1.2% and Biogen Idec ( BIIB), up 0.3%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.17 (-0.3%) to $58.73 on heavy volume. Thus far, 2.7 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $58.70-$59.20 after having opened the day at $59.10 as compared to the previous trading day's close of $58.90. AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $73.7 billion and is part of the health care sector. The company has a P/E ratio of 11.8, below the S&P 500 P/E ratio of 17.7. Shares are up 24.6% year to date as of the close of trading on Thursday. Currently there are no analysts that rate AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.